Venetoclax: a new wave in haemato-oncology

• Cancer cells survive via overexpressed anti-apoptotic BCL2 proteins• Venetoclax is highly selective BCL2 inhibitor with acceptable toxicity profile• It overcomes resistance to ibrutinib and idelalisib in chronic lymphocytic leukemia• Effective in a subset of multiple myeloma with high with t(11;14)• Synergic activity with low-dose cytarabine, 5-azacytidine in acute myeloid leukemia

Source: Experimental Hematology - February 22, 2018 Category: Hematology Authors: Jana Mihalyova, Tomas Jelinek, Katerina Growkova, Matous Hrdinka, Michal Simicek, Roman Hajek Tags: Review Source Type: research